Tests cangrelor dosing in adults with coronary artery disease
Tests adjusted cangrelor infusion doses for blood-thinning control in adults with coronary artery disease.
Plain-language title generated from the registry record
Registry title: The Bridging Antiplatelet Therapy With Cangrelor 2 Study
Key facts
- Where
- Jacksonville, United StatesSee the site
- Phase
- Phase 4
Where in United States
- University of Florida - JacksonvilleJacksonville, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Florida
- Trial code
- NCT07225842
- Record updated
- 6 November 2026
- Original description
The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.Read full original descriptionShow less
The Bridging Antiplatelet Therapy With Cangrelor 2 (BRIDGE 2) Study: A Pilot Prospective Cohort, Pharmacodynamic Study of Tailored Cangrelor Bridging Dosing Regimens
The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.
Inclusion: Any patient receiving bridging with standard-dose cangrelor infusion rate of 0.75 mcg/Kg/min for at least two hours as part of their standard of care; Age ≥18 years; Provide written informed consent.
Exclusion: Need for urgent surgery; Exposure to any oral P2Y12 inhibitor, oral anticoagulant or glycoprotein IIb/IIIa inhibitor within 48 hours; Known allergy, and hypersensitivity, or contraindication to cangrelor, mannitol, sorbitol, or microcrystalline cellulose; Confirmed or suspected pregnancy (in woman of child-bearing potential) or lactating females.